Rize Oncology Inc.
RZONF
$0.16
$0.1639,900.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.06% | 8.63% | 34.46% | 16.15% | 1.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.17% | 62.13% | 49.46% | 0.35% | -21.17% |
| Operating Income | -113.17% | -62.13% | -49.46% | -0.35% | 21.17% |
| Income Before Tax | -127.17% | -73.15% | -62.03% | -7.02% | 19.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -127.17% | -73.15% | -62.03% | -7.02% | 19.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.17% | -73.15% | -62.03% | -7.02% | 19.96% |
| EBIT | -113.17% | -62.13% | -49.46% | -0.35% | 21.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -16.20% | -1.68% | -9.21% | 7.84% | 10.13% |
| Normalized Basic EPS | -18.18% | -2.70% | -10.64% | 7.37% | 10.20% |
| EPS Diluted | -16.20% | -1.68% | -9.21% | 7.84% | 10.13% |
| Normalized Diluted EPS | -18.18% | -2.70% | -10.64% | 7.37% | 10.20% |
| Average Basic Shares Outstanding | 96.68% | 69.27% | 36.57% | 7.87% | -16.24% |
| Average Diluted Shares Outstanding | 96.68% | 69.27% | 36.57% | 7.87% | -16.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |